1.Effect Evaluation of PDCA Cycle Management on Perioperative Prophylactic Application of Antibiotics in TypeⅠIncision Surgery of Orthopedics Department
Yane QIN ; Hui ZHONG ; Biao CHEN ; Yinge LIANG ; Huiling ZHANG ; Guihuan JIANG ; Junlin WU
China Pharmacy 2017;28(5):690-693,694
OBJECTIVE:To evaluate the effects of PDCA cycle management on perioperative prophylactic application of antibiotics in typeⅠincision surgery of orthopedics department. METHODS:In retrospective analysis,512 discharge medical records, 861 ones and 1 070 ones were selected from our hospital before PDCA cycle management(Jan.-Dec. 2013,before intervention group), after first cycle of PDCA cycle management (Jan.-Dec. 2014,first intervention group) and after second cycle of PDCA cycle management(Jan.-Dec. 2015,second intervention group),respectively. The perioperative prophylactic application of antibiotics was analyzed comparatively before and after continuous intervention. RESULTS:After 2 cycles of PDCA cycle management intervention, the constituent ratio of internal fixation in orthopedics department increased significantly;utilization ratio of antibiotics,the rate of rational type,medication ratio 0.5-1 h before surgery,the rate of rational treatment course,the proportion of antibiotics use in accordance with indications increased from 50.20%,98.08%,93.77%,6.61%,82.10% to 58.41%,100%,99.04%,52.00%, 99.04%,respectively. The number of antibiotics type decreased from 4 to 2;the proportion of cephazolin increased significantly while that of clindamycin decreased significantly compared to before intervention. Postoperative prophylactic medication course decreased from(4.63 ± 2.42)d to(1.61 ± 0.75)d;the proportion of patients with medication course <24 h or ranged 24-48 h increased significantly, while those with medication course>72 h decreased significantly, with statistical significance (P<0.05). CONCLUSIONS:PDCA cycle management improves the rational rate of perioperative prophylactic application of antibiotics in typeⅠincision surgery of orthopedics department in our hospital. The prophylactic medication course of our hospital is not yet fully controlled within 24 h so it should be further intervened.
2.The application of data gloves in the evaluation of patients with hand injuries
Peisong XIA ; Jianhua LI ; Liang ZHONG ; Yinge CHEN ; Yuxin PENG
Chinese Journal of Physical Medicine and Rehabilitation 2018;40(12):919-922
Objective To develop a data glove evaluation system to assist rehabilitation physicians and therapists in assessing the degree of rehabilitation of hand-wounded patients. Methods A data glove containing 136-axis inertial sensors was designed and produced. It was tested on 10 healthy subjects and 3 hand trauma pa-tients admitted to the Department of Rehabilitation Medicine at Run Run Shaw Hospital. The glove transmitted ac-celeration and angular velocity components in the X, Y and Z directions to a computer terminal, allowing the ben-ding angles of the subject′s finger joints to be calculated. Traditional protractor measurements were used to verify to what extent the data glove accurately reflected the hand and joint activity. Results Compared with the traditional protractor measurement method, the data glove quickly gave accurate maximum bending angles both in healthy and hand-wounded subjects . Such data can facilitate the rehabilitation of hand injuries. Conclusions The data glove produced in this study can effectively assist rehabilitation doctors and therapists in assessing the recovery of hand-injured patients.
3.Efficacy of recombinant human TNK tissue-type plasminogen activator and adenosine injection for acute ST-segment elevation myocardial infarction
Liu LI ; Qinghou ZHENG ; Yinge ZHAN ; Le WANG ; Qincong CHEN ; Shuo WANG
Journal of Xi'an Jiaotong University(Medical Sciences) 2024;45(5):794-800
【Objective】 To evaluate the efficacy of recombinant human TNK tissue-type plasminogen activator and adenosine injection through guiding in treating acute ST-segment elevation myocardial infarction (ASTEMI) in emergency primary percutaneous coronary intervention (PPCI). 【Methods】 Patients with ASTEMI who chose to receive emergency PPCI were randomly divided into control group and treatment group according to a digital random table method. The control group received conventional treatment of PPCI. If the infarct-related artery (IRA) reached TIMI flow grade 3 after PPCI, the operation was terminated. If TIMI flow was ≤2, then a guide catheter to inject sodium nitroprusside, nitroglycerin, and tirofiban into the coronary artery to improve coronary microcirculation dysfunction (CMD) was applied until the IRA reached TIMI flow grade 3. The treatment group received the conventional treatment of PPCI, and after opening of the IRA during the operation, a guide catheter to inject recombinant human TNK tissue-type plasminogen activator (8 mg) and adenosine (200 μg) into the coronary artery was applied. If the IRA reached TIMI flow grade 3, the operation was terminated. If TIMI flow was ≤2, then adenosine injection was re-applied to improve CMD until the IRA reached TIMI flow grade 3. Observation indicators were as follows: ① myocardial injury indicators: cardiac troponin I (cTnI), creatine kinase isoenzyme (CK-MB), and N-Terminal pro-brain natriuretic peptide (NT-pro BNP) levels before and 12 h, 24 h, 36 h, and 48 h after surgery; ② myocardial perfusion indicators: corrected TIMI frame count (CTFC) after surgery and ST segment regression value (STR) at 90 min after surgery; ③ degree of myocardial ischemia: rest D-SPECT+adenosine stress D-SPECT examination at day 3 after surgery, observation of myocardial perfusion total score under 17 segment distribution and myocardial ischemia total segment number; ④ adverse drug reactions at day 30 after surgery: subcutaneous ecchymosis, gingival bleeding, gastrointestinal bleeding, urinary bleeding, hemoglobin decline, and cerebral hemorrhage; ⑤ major adverse cardiovascular events (MACE) at day 30 after surgery: cardiac death, myocardial infarction, heart failure, and target vessel revascularization. 【Results】 ① Myocardial injury indicators: There was no significant difference in the levels of cTnI, CK-MB, or NT-pro BNP before surgery between the two groups (all P>0.05). The myocardial injury indicators were significantly lower in the treatment group than in the control group at 12 hours after surgery (all P<0.05), and then showed a downward trend. There was no significant difference between the two groups at 48 hours after surgery (all P>0.05). ② Myocardial perfusion indicators: CTFC in the treatment group was significantly better than that in the control group after surgery (P<0.05). Using the rank sum test, the STR was significantly better in the treatment group than in the control group at 90 minutes after surgery (Z=2.437, P=0.014). ③ myocardial ischemia: Both groups underwent rest D-SPECT+adenosine stress D-SPECT examination at 3 days after surgery. Under the distribution of 17 myocardial segments, the total score of myocardial perfusion and the total number of myocardial ischemia segments in the treatment group were significantly better than those in the control group (all P<0.05). ④ Adverse drug reactions 30 days after surgery: There was no significant difference in subcutaneous ecchymosis, gingival bleeding, gastrointestinal bleeding, urinary system bleeding, hemoglobin decline, or cerebral hemorrhage between the two groups (P>0.05). ⑤ MACE 30 days after surgery: There was no significant difference in cardiac death, myocardial infarction, heart failure, target vessel revascularization, or total MACE between the two groups (P>0.05). 【Conclusion】 The intra-coronary injection of recombinant human TNK tissue-type plasminogen activator and adenosine injection through a guiding catheter in emergency PPCI is safe and effective for the treatment of ASTEMI. It can improve myocardial injury, myocardial perfusion, and myocardial ischemia.